GlycoMimetics, Inc. (GLYC)
Pre-market:
| Previous close | 0.2994 |
| Open | 0.2990 |
| Bid | 0.2862 x 1000 |
| Ask | 0.2934 x 1000 |
| Day's range | 0.2750 - 0.2990 |
| 52-week range | 0.2600 - 3.5300 |
| Volume | |
| Avg. volume | 1,574,927 |
| Market cap | 18.624M |
| Beta (5Y monthly) | 2.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md., May 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemothera
- Business Wire
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
ROCKVILLE, Md., April 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
- Business Wire
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
ROCKVILLE, Md., March 27, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million.
